Thalassemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
[Lowest Price Guaranteed: $2,000]

Published by Delve Insight: 30 May 2017 | 86590
Related Topics: Drug

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Thalassemia-Global
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email bioportfolio97@gmail.com.

Introduction

DelveInsight’s Report, “Thalassemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Thalassemia Report is to understand the market and pipeline status of the drugs around the Thalassemia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Thalassemia. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:

• A snapshot of the global Market and Phase III therapeutics scenario for Thalassemia.

• A review of the marketed products under prescription for Thalassemia, regulatory information and marketing status.

• Coverage of global patent coverage and detailed commentaries on the US patent challenges.

• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

• Product profiles for marketed products for Thalassemia with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

• Coverage of API Manufacturers for Thalassemia drugs in the United States, Europe and Asian Regions with location details.

• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Thalassemia drugs.

• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Thalassemia drugs.

• Coverage of Thalassemia Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.

• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.

• Key discontinued Marketed products.

• Global Sales Figure to 2018.

Reasons to buy

• Evaluate the marketing status and exclusivity details of Thalassemia key products to exploit opportunities for generic drug development opportunities.

• Identify and understand important and diverse types of therapeutics under Phase III development for Thalassemia.

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Thalassemia.

• API intelligence over marketed drugs forThalassemiaand gaining primary intelligence over active ingredients manufacturers across the globe.

• API intelligence over leading Phase III Pipeline drugs.

• Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.

• Understanding the scope of the Phase III Drugs with nil regulatory filings.

• Understanding the chemical route of synthesis of approved drugs for Thalassemia.

• Uncovering opportunities in the rapidly growing US market.

Table of Contents
for Thalassemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

List Of Tables
in Thalassemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

• Thalassemia Therapeutic Market, US, Marketed Drugs by Application Type, 2017

• Thalassemia Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017

• Thalassemia Therapeutic Market, US, (Year), 2017

• Thalassemia Marketed Drugs, API Manufacturers by US DMF Status, 2017

• Thalassemia Marketed Drugs, US DMF Status Drug Specific (Number), 2017

• Thalassemia Drugs, API Manufacturers, Europe by Country, 2017

• Thalassemia Drugs, API Manufacturers, India by State, 2017

• Thalassemia Drugs, API Manufacturers, China by Province, 2017

• Thalassemia Drugs, API Manufacturers by Geography 2017

• Thalassemia Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017

• Thalassemia Therapeutic Market, Global Sales-2018 (in million USD)

• API Manufacturers for Drug, 2017

• Phase III Drugs for Thalassemia, 2017

• Discontinued Drugs for Thalassemia, 2017

List Of Figures, Charts and Diagrams
in Thalassemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

• Thalassemia Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017

• Thalassemia Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017

• Thalassemia Therapeutic Market, US, (Year), 2017

• Thalassemia Marketed Drugs, API Manufacturers by US DMF Status (%), 2017

• Thalassemia Marketed Drugs, US DMF Status Drug Specific (Number), 2017

• Thalassemia Drugs, API Manufacturers, Europe by Country, 2017

• Thalassemia Drugs, API Manufacturers, India by State, 2017

• Thalassemia Drugs, API Manufacturers, China by Province, 2017

• Thalassemia Drugs, API Manufacturers by Geography 2017

• Thalassemia Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017

• Thalassemia Therapeutic Market, Global Sales 2018 (in million USD)

• Drug, Patent/Exclusivity Expiry (Year), 2017

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

86590 | DIIR2017424

Number of Pages

100

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Thalassemia - Pipeline Review, H1 2018
Thalassemia - Pipeline Review, H1 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healt...
27 Feb 2018 by Global Markets Direct USD $2,000 More Info
Thalassemia -Epidemiology Forecast to 2025
DelveInsight “Thalassemia - Epidemiology Forecast To 2025” provides an overview of the epidemiology ...
10 Oct 2017 by Delve Insight USD $2,750 More Info
Thalassemia - Market Insights, Epidemiology and Market Forecast – 2025
DelveInsight’s “Thalassemia - Market Insights, Epidemiology and Market Forecast - Market Insights, E...
10 Oct 2017 by Delve Insight USD $5,750 More Info
Thalassemia - Pipeline Review, H2 2017
Thalassemia - Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healt...
22 Aug 2017 by Global Markets Direct USD $2,000 More Info
Thalassemia - Pipeline Review, H2 2017
Thalassemia - Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healt...
22 Aug 2017 by Global Markets Direct USD $2,000 More Info
Thalassemia - Epidemiology Forecast To 2023
DelveInsight “Thalassemia - Epidemiology Forecast To 2023” provides an overview of the epidemiology ...
31 May 2017 by Delve Insight USD $2,750 More Info
Thalassemia-Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Thalassemia - Market Insigh...
30 May 2017 by Delve Insight USD $4,950 More Info
Thalassemia-Pipeline Insights, 2017
DelveInsight’s, “ Thalassemia-Pipeline Insights, 2017”, report provides in depth insights on the pip...
30 May 2017 by Delve Insight USD $1,250 More Info
Thalassemia - Pipeline Review, H1 2017
Thalassemia - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healt...
22 Mar 2017 by Global Markets Direct USD $2,000 More Info
Thalassemia Global Clinical Trials Review, H2, 2016
Thalassemia Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Thala...
31 Aug 2016 by Global Data USD $2,500 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...